echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Two new therapeutic drugs for blood tumors are on the market in China!

    Two new therapeutic drugs for blood tumors are on the market in China!

    • Last Update: 2020-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Xi'an Yangsen Pharmaceutical Co., Ltd. announced that a new therapeutic drug for the treatment of two blood tumors, Yiyi (Ibtini capsules), has been officially launched in China. The drug is known to be an oral Bruton tyrosine kinase (BTK) inhibitor and is suitable for patients with chronic lymphocytic leukemia/small lymphocyte lymphoma who have previously received at least one treatment, as well as patients with cell lymphoma who have previously received at least one treatment.
    Following the "priority review" of the Drug Review Center of the State Food and Drug Administration in December last year, ibtinib capsules were approved by the State Food and Drug Administration on August 24 this year and were officially launched 69 days after approval, providing an important new treatment option for long-awaited Chinese patients."Chronic lymphocytic leukemia/small lymphocytic lymphoma and set cell lymphoma are two rare diseases, with an estimated annual incidence rate of 0.27/100,000 and 0.16/100,000 in China, respectively," stressed Professor Ma Jun, president of the China Anti-Lymphoma Alliance and director of Harbin Hematic Oncology Institute,
    Professor Ma Jun, President of the China Anti-Lymphoma Alliance and Director of Harbin Hematic Tumor Research Institute. The recurrence rate of these two diseases is high, but the current treatment methods are limited. It is worth noting that china has not had new drugs for the treatment of these two diseases in the past 8 years, resulting in drug resistance and recurrence of patients facing adverse prognosis and no drug available situation. As a result, both patients and doctors are eagerly awaiting a new treatment option that is well tolerated and more effective. "
    five international Phase II/III trials and an Asia-Pacific Phase III study evaluating the safety and effectiveness of Ibtini capsules for the treatment of chronic lymphocytic leukemia/small lymphocyte lymphoma and cell lymphoma."Clinical trials in Both Chinese patients and international multi-centers have shown that patients with chronic lymphocytic leukemia/small lymphocyte lymphoma who received at least one treatment had a reduced risk of death or progression by about 80 percent after receiving ibutini capsules, meaning that their median survival was close to similar to those of the same age group," said Li Bin, vice president of medical affairs at Xi'an Yangsen Pharmaceutical Co., Ltd.,
    .
    currently, ibtini capsules cover 49 cities. At the same time, the China Primary Health Care Foundation has launched the "Billion New Life- Lymphoma Patient Assistance Program" to provide ibtinib capsule drug assistance to low-income lymphoma patients. The drug has been approved in 86 countries and has been used in more than 90,000 patients worldwide.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.